Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, was introduced to regulate the quality, efficacy, and safety of therapeutic goods sold in Australia. This includes medicines, medical devices, and blood and blood components used for therapeutic purposes. The Act provides a framework for the regulation of therapeutic goods throughout their lifecycle, from research and development through to manufacturing, advertising, and post-market surveillance. One of its primary objectives is to protect public health by ensuring that only therapeutic goods that meet required standards are available for use in Australia. In this context, the Act empowers the Therapeutic Goods Administration to revoke licenses of manufacturers who do not comply with regulatory standards, as demonstrated in the revocation of Slade Health Pty Ltd’s manufacturing license under Section 41 of the Act.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, and importation of therapeutic goods in Australia, including medicines, medical devices, blood, and tissues. The Act regulates these goods to ensure they are of acceptable quality, safety, and efficacy. It applies to both Australian and overseas manufacturers, importers, and suppliers who engage in activities related to therapeutic goods within Australia's jurisdiction. The geographic reach of the Act is national, encompassing the entire Commonwealth of Australia, including all states and territories. The Act provides for the licensing of therapeutic goods manufacturing, which is mandatory for entities that wish to manufacture therapeutic goods within the country. The revocation of a licence, as seen in the revocation of Slade Health Pty Ltd’s licence, is a significant enforcement mechanism under the Act, reflecting its role in maintaining the quality and safety standards of therapeutic goods. The Act also allows for the exclusion of certain goods from its purview, such as those regulated under other specific legislations, and may include exemptions or thresholds for smaller entities or specific categories of goods through subordinate instruments.

Key Provisions

The key provision of the Therapeutic Goods Act 1989 (Section 41(1)(d)) allows the Secretary to revoke a manufacturer's licence upon the manufacturer's request or under certain circumstances. In this specific instance, Slade Health Pty Ltd has requested the revocation of their Licence No. MI-14072006-LI-001389-11, which was issued for the manufacture of therapeutic goods at their premises located at 218-228 Stanley Street, West Melbourne, VIC, 3003. The revocation is effective from the date of publication, which is 3 September 2017. Under the Act, manufacturers of therapeutic goods must comply with a number of obligations and requirements to maintain their licence. These include adhering to good manufacturing practices, ensuring the quality and safety of the products they manufacture, and maintaining proper records and documentation. The revocation of Slade Health Pty Ltd’s licence indicates that they have either voluntarily relinquished their ability to manufacture therapeutic goods or have failed to meet the regulatory requirements, prompting their request for revocation. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in both civil and criminal consequences. For instance, unauthorised manufacturing of therapeutic goods can lead to penalties such as fines or imprisonment. However, in this case, since the revocation was at the request of the manufacturer, no penalties are applicable as it is a voluntary action by the company. Nonetheless, the revocation will have legal implications for Slade Health Pty Ltd, including the inability to manufacture therapeutic goods unless a new licence is obtained under the Act. The Therapeutic Goods Act 1989 also outlines the process for the revocation of a manufacturing licence. This includes the requirement for the Secretary to provide written notice of the revocation, which in this case was signed by Hongxia Jin, Delegate of the Secretary for the Therapeutic Goods Administration. The notice must specify the reasons for the revocation and the effective date, ensuring transparency and legal compliance. The Act’s provisions aim to protect public health by ensuring that only those manufacturers who meet the necessary standards are permitted to produce therapeutic goods.